Sign in
Not yet taking people in United StatesPhase 2

MDMA-AT for PTSD in Young Adults With Childhood Trauma

Key facts

Who runs it
Jenna M. Traynor
Where
Belmont, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
15 people, planned
Started
31 Oct 2026
Expected to end
1 Dec 2028
Type of study
Interventional
Treatments tested
  • MDMA assisted psychotherapy
Record updated
20 August 2026

Who can take part

Age
18 years to 26 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (62)Hide the full registry criteria

Who can take part

  • Demographic and Participant Information
  • Between the ages of 18-26 years old upon signing the written consent form
  • Proficient in speaking and reading English
  • Capable of providing informed consent
  • Is able to swallow pills
  • Willing and able to be contacted by phone throughout the study
  • Resides in the United States
  • Meets DSM-5 criteria for PTSD with sufficient severity assessed at study screening
  • History of index Criterion A trauma that occurred in childhood
  • Must agree to inform the research team within 48 hours of any emerging or new medical conditions and/or procedures
  • Must provide an emergency contact
  • Has someone to drive them home after each MDMA-AT session (or agrees to take a taxi/rideshare while accompanied by a close other)
  • Agree not to drive for 24 hours after each MDMA-AT session
  • Agree to return to place of residence immediately after each MDMA-AT session, and stay there until the next morning
  • Has a trusted close other who is at least 18 years of age that agrees to stay with them throughout the night until the morning after each MDMA-AT session, and is willing to attend the ICF meeting and co-sign the ICF
  • Agree to not participate in any other interventional clinical trials from baseline to the primary study endpoint
  • Is willing and able to refrain from taking any psychiatric medications during the study period
  • Agrees to abstain from other medications (e.g., over the counter, PRN medications, etc) unless approval from PI has been obtained; If able to become pregnant:
  • Must have a negative pregnancy screen during study screening and on the morning of each MDMA-AT session
  • Must agree to use adequate birth control for the duration of participation
  • Has a primary care provider (PCP)
  • Has a regular outpatient mental health treater (e.g., psychiatrist, psychologist) that will resume care for the participant following completion or termination of study participation

Who cannot take part

  • For cannabis use and alcohol use disorders without physiological dependence, must agree to be abstinent from alcohol and cannabis for one week prior to and following each MDMA-AT session
  • Has a current restrictive eating disorder with current low body-mass index, or any eating disorder with active purging, currently, or in the 3 months prior to enrollment
  • Has used MDMA in the month prior to enrollment
  • Has participated in a previous MDMA-AT for PTSD clinical trial
  • Has hypersensitivity to any ingredient of the Investigational Product
  • Requires ongoing concomitant therapy with a psychiatric drug, excluding gabapentin
  • Is currently receiving trauma-focused psychotherapy and unwilling or unable to put treatment on hold for the duration of active study participation
  • Has received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment
  • Has received ketamine infusions and/or ketamine-assisted therapy in the 8 weeks prior to enrolment
  • Currently on methadone maintenance treatment
  • Any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate
  • Meets DSM-5 criteria for any current substance use disorder, other than alcohol, cannabis, or nicotine use disorder
  • Meets DSM-5 criteria for current cannabis or alcohol use disorder with physiological dependence, or physiological dependence cannot be determined
  • Meets other DSM-5 criteria for serious mental illness, as assessed by the DART or through clinical interviews or observations
  • Diagnosed major neurodevelopmental or neurological disorder
  • Scaled score on the Test of Premorbid Functioning that is suggestive of possible cognitive impairment
  • Has symptomatic liver disease or significant liver enzyme elevation
  • History of concussion with loss of consciousness ≥ 24 hours or traumatic brain injury
  • History of hyponatremia or hyperthermia
  • Uncontrolled hypertension
  • History of arrythmia (e.g., atrial or ventricular arrhythmia) at any time, other than occasional premature atrial contractions (PACs) or premature ventricular contractions (PVCs) in the absence of ischemic heart disease, within 12 months of screening
  • History of tachycardia or cardiac disorder
  • Has Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation
  • Is currently engaged in compensation litigation whereby financial gain would be achieved from prolonged psychiatric symptoms
  • marked Baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds (ms) in males and >460 ms in females corrected by Fridericia's formula). For transgender or non- binary participants, QTc interval will be evaluated based on sex assigned at birth, unless the participant has been on hormonal treatment for five or more years
  • History of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Requires use of concomitant medications that prolong the QT/QTc interval
  • Recently attempted suicide or engaged in high risk self-injury or is otherwise assessed to be at imminent risk of suicide by study staff
  • In the opinion of the PI, would present a serious risk to others as established through study screening measures or clinical observations
  • Has used MDMA excessively in the past
  • Requires the use of opiates for pain management
  • Weighs less than 48 kg (105 lbs)
  • Standard MRI contraindications
  • Is pregnant or nursing, planning to become pregnant during the course of the study, or is able to become pregnant and not practicing an effective means of birth control
  • In the opinion of the PI, participant's current place of residence is unstable
  • Requires a legally authorized representative to provide informed consent
  • In the opinion of the study PI, is not able to adhere to the requirements for procedures, attendance and timing of visits, and observe limits regarding study staff time and support
  • Is participating in another interventional clinical trial at any point from study screening to the primary study endpoint (i.e., post-treatment visit)
  • Does not reside in the US
  • Substantial colorblindness sufficient to impede performance on the fMRI tasks

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Posttraumatic stress disorder

Where in United States

  • McLean HospitalBelmont, United StatesContact: Alexandra Velev, BANot yet recruiting

About the trial

What the trial wants to find out

This study is testing a new, emerging treatment for young adults (ages 18-26) with Posttraumatic Stress Disorder (PTSD). The treatment is combining the substance, MDMA, with up to three psychotherapy sessions, also known as MDMA-Assisted Therapy (MDMA-AT).

Read full original descriptionShow less

The main questions it aims to answer are:

* Is the treatment safe and feasible to administer? * Does the treatment improve PTSD symptoms?

Participants will be asked to:

* Complete screening procedures, including a medical and psychiatric evaluation to ensure safe participation * Attend up to three preparatory talk therapy sessions prior to the first MDMA-AT dosing session * Attend three integration talk therapy sessions after each MDMA-AT dosing session * Attend up to three total MDMA-AT dosing sessions * Complete assessments from baseline to 38-weeks post-baseline * Complete a fMRI scan at baseline and at 18-weeks post-treatment * Complete self-report measures and ecological momentary assessments (EMAs) across the study period

The group in the trial

  • Experimental: MDMA-AT for PTSDTreatment being tested

    Open-label MDMA-assisted therapy (up to three sessions of 120mg MDMA)

    Treatment: MDMA assisted psychotherapy

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder in Young Adults With Childhood Trauma: An Open-Label Pilot Study
Criteria questions
Built from NCT07765693, who can take part
Record updated
20 August 2026